

ABSTRACT OF THE DISCLOSURE

Novel methods and combinations for the treatment and/or prophylaxis of a hyperlipidemic condition or disorder in a subject, wherein the methods comprise the administration of one or more HMG Co-A reductase inhibitors and one or more ASBT
5 inhibitors selected from the specific group of compounds described herein, and the combinations comprise one or more HMG Co-A reductase inhibitors and one or more of said apical sodium co-dependent bile acid transport inhibitors.